Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-15 · accession 0001415889-25-008558 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-18 | 2025-03-15+ | MIRM | Howe Jolanda | SVP, Gbl Ctrl | M - OptEx | $2.94 | +58.2K | 59.5K | +4,370% | +$171.2K |
| DM | 2025-03-18 | 2025-03-17 | MIRM | Howe Jolanda | SVP, Gbl Ctrl | S - Sale+OE | $44.35 | -57.6K | 6,647 | -90% | -$2.55M |
| DM | 2025-03-18 | 2025-03-15+ | MIRM | Howe Jolanda | SVP, Gbl Ctrl | M - OptEx | $0.00 | -58.2K | 2,658 | -96% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-15 | M | A | 5,315 | — | 9,547 | D | — | — | (F1) Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Common | Common Stock | 2025-03-17 | M | A | 52,900 | $2.94 | 59,547 | D | — | — | |
| 3 | Common | Common Stock | 2025-03-17 | S | D | 50,111 | $44.33 | 9,436 | D | — | — | (F4) The weighted average sale price for the transaction reported was $44.33410, and the range of prices were between $43.695 and $44.695. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 4 | Common | Common Stock | 2025-03-17 | S | D | 2,789 | $44.75 | 6,647 | D | — | — | (F5) The weighted average sale price for the transaction reported was $44.74811, and the range of prices were between $44.70 and $44.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 5 | Common | Common Stock | 2025-03-17 | S | D | 1,806 | $44.36 | 4,841 | D | — | — | (F6) The weighted average sale price for the transaction reported was $44.35923, and the range of prices were between $43.81 and $44.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 6 | Common | Common Stock | 2025-03-17 | S | D | 2,900 | $44.21 | 6,647 | D | — | — | |
| 7 | Derivative | Stock Option (right to buy) | 2025-03-17 | M | D | 52,900 | $0.00 | 0 | D | $2.94 · — to 2029-03-11 | 52,900 Common Stock | (F8) The stock option is fully vested. |
| 8 | Derivative | Performance Restricted Stock Units | 2025-03-15 | M | D | 5,315 | $0.00 | 2,658 | D | — · — to — | 5,315 Common Stock | (F1) Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F7) The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. |